PMID: 15385734Sep 24, 2004Paper

Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir

Journal of Acquired Immune Deficiency Syndromes : JAIDS
Constance DelaugerreStéphane Blanche

Abstract

Predictive factors of the virologic success of the use of lopinavir/ritonavir (LPV/r) in HIV-infected children are unknown, especially in children who have been pretreated with protease inhibitors (PIs). This longitudinal, single-center, observational study included 69 children (21 PI-naive and 48 PI-experienced) who had received LPV/r for at least 3 months. The mean (+/- SD) age was 10.3 +/- 4.8 years, and the mean baseline of CD4 percentage and HIV-1 RNA was 14.9% +/- 9.8% and 4.8 +/- 1.05 log10 copies/mL, respectively. The mean duration of follow-up was 16.5 +/- 8.3 months. At 6, 12, and 18 months, 52%, 57%, and 49% of all children, respectively, had a viral load less than 50 copies/mL. The risk of virologic failure, defined as 2 consecutive viral loads greater than 1000 copies/mL, was significantly higher when the children were previously treated with PIs and when the baseline LPV mutation score exceeded 3 mutations. In the pretreated children, the ratio of the plasma LPV maximal concentration to the baseline LPV score mutation was also associated with failure, independently of resistance score. Finally, in children failing an LPV-containing regimen, accumulation of additional PI-associated resistance mutations was evidence...Continue Reading

References

Mar 21, 2002·The Lancet Infectious Diseases·Annemarie M C van RossumRonald de Groot
Jun 28, 2002·The New England Journal of Medicine·Sharon WalmsleyUNKNOWN M98-863 Study Team
Aug 17, 2002·Antimicrobial Agents and Chemotherapy·Bernard MasquelierUNKNOWN Groupe d' Epidémiologie Clinique du SIDA en Aquitaine
Nov 30, 2002·International Journal of Antimicrobial Agents·Pablo BarreiroVincent Soriano
Mar 14, 2003·The Pediatric Infectious Disease Journal·Xavier Sáez-LlorensEugene Sun
Mar 29, 2003·Drugs·Risto S Cvetkovic, Karen L Goa
Jul 19, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Laura MonnoGioacchino Angarano
Aug 23, 2003·The Journal of Infectious Diseases·Dechao Wang, Brendan Larder

❮ Previous
Next ❯

Citations

Aug 11, 2005·Current HIV/AIDS Reports·Michael Neely, Andrea Kovacs
May 21, 2005·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·J M Treluyer
May 3, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tommy F Liu, Robert W Shafer
Sep 5, 2009·The Journal of Antimicrobial Chemotherapy·Thanyawee PuthanakitKiat Ruxrungtham
May 2, 2009·Current Opinion in Infectious Diseases·Ravindra K GuptaDeenan Pillay
Mar 30, 2017·PloS One·Patricia Rojas SánchezUNKNOWN Madrid Cohort of HIV-1 Infected Children and Adolescents Integrated in the Paediatric Branch of the Spanish National AIDS Ne
Jul 4, 2007·Journal of Medical Virology·Constance DelaugerreStéphane Blanche
Oct 13, 2005·The Pediatric Infectious Disease Journal·Jintanat AnanworanichUNKNOWN HIV-NAT 017 Study Team
Feb 1, 2006·The Journal of Antimicrobial Chemotherapy·Salvador ResinoUNKNOWN Spanish Group of HIV Infection
Oct 1, 2005·The Journal of Antimicrobial Chemotherapy·José Luis JiménezUNKNOWN Spanish Group of Paediatric HIV Infection
Jun 4, 2008·The Pediatric Infectious Disease Journal·Pope KosalaraksaUNKNOWN HIV-NAT 017 Study Team
Jul 11, 2006·Drugs·Vicki Oldfield, Greg L Plosker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.